GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » SI-BONE Inc (NAS:SIBN) » Definitions » ROC (Joel Greenblatt) %

SI-BONE (SI-BONE) ROC (Joel Greenblatt) % : -91.91% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is SI-BONE ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. SI-BONE's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -91.91%.

The historical rank and industry rank for SI-BONE's ROC (Joel Greenblatt) % or its related term are showing as below:

SIBN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -413.34   Med: -273.51   Max: -89.52
Current: -89.52

During the past 8 years, SI-BONE's highest ROC (Joel Greenblatt) % was -89.52%. The lowest was -413.34%. And the median was -273.51%.

SIBN's ROC (Joel Greenblatt) % is ranked worse than
67.88% of 850 companies
in the Medical Devices & Instruments industry
Industry Median: 0.48 vs SIBN: -89.52

SI-BONE's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 16.80% per year.


SI-BONE ROC (Joel Greenblatt) % Historical Data

The historical data trend for SI-BONE's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SI-BONE ROC (Joel Greenblatt) % Chart

SI-BONE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -413.34 -340.45 -253.24 -172.70 -97.09

SI-BONE Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -105.41 -93.94 -87.42 -78.54 -91.91

Competitive Comparison of SI-BONE's ROC (Joel Greenblatt) %

For the Medical Devices subindustry, SI-BONE's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


SI-BONE's ROC (Joel Greenblatt) % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, SI-BONE's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where SI-BONE's ROC (Joel Greenblatt) % falls into.



SI-BONE ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(19.988 + 22.335 + 1.943) - (6.27 + 0 + 11.699)
=26.297

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(21.953 + 20.249 + 3.173) - (6.877 + 0 + 15.163)
=23.335

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of SI-BONE for the quarter that ended in Dec. 2023 can be restated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-40.376/( ( (19.521 + max(26.297, 0)) + (18.706 + max(23.335, 0)) )/ 2 )
=-40.376/( ( 45.818 + 42.041 )/ 2 )
=-40.376/43.9295
=-91.91 %

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SI-BONE  (NAS:SIBN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


SI-BONE ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of SI-BONE's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


SI-BONE (SI-BONE) Business Description

Traded in Other Exchanges
N/A
Address
471 El Camino Real, Suite 101, Santa Clara, CA, USA, 95050
SI-BONE Inc is a medical device company, that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain.
Executives
Anshul Maheshwari officer: Chief Financial Officer 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Davis Timothy E Jr director 5677 AIRLINE ROAD, ARLINGTON TN 38002
Anthony J Recupero officer: Chief Commercial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Jeffrey W Dunn director, officer: Chairman, President & CEO C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Laura Francis officer: Chief Financial Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
John Gordon Freund director, 10 percent owner 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael A Pisetsky officer: GC & Chief Compliance Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Karen A Licitra director C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Helen Loh director 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Mika Nishimura director 471 EL CAMINO REAL, SANTA CLARA CA 95050
Skyline Venture Partners V Lp 10 percent owner 525 University Avenue, Suite 520, Palo Alto CA 94301
W Carlton Reckling officer: CMO and VP, Medical Affairs C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Scott A Yerby officer: Chief Technology Officer C/O SI-BONE, INC., 471 EL CAMINO REAL, SUITE 101, SANTA CLARA CA 95050
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451